Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 36

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 36
---
 management
and board of directors.

<div align='center'>17</div>

Our operations and the operations of our contract manufacturer may be disrupted as a result of the obligation of Israeli citizens to perform military service.

Many Israeli citizens are obligated to perform
one month, and in some cases more, of annual military reserve duty until they reach the age of 45 (or older, for reservists with certain
occupations) and may be called to active duty. In connection with the Israeli security cabinet’s declaration of war against Hamas
and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate
military service. One of our employees and consultants (and their spouses or partners) in Israel have been called, and additional employees
(or their spouses or partners) may be called, for service in the current or future wars or other armed conflicts with Hamas, and such
persons may be absent for an extended period of time. As a result, our operations in Israel may be disrupted by such absences, which
disruption may materially and adversely affect our business, prospects, financial condition and results of operations. Currently, none
of the employees engaged in R&D has been on military reserve duty. All employees except for one are above the age of 45 and are not
likely to be called for services.

Our future sales may be adversely affected by boycotts of Israel.

While we currently do not sell any projects and
do not have business agreements or arrangements to sell our product candidates in the future upon the FDA’s approval, we may experience
difficulties to sell our products in the future to certain countries. Several countries, principally in the Middle East, restrict doing
business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli
companies whether as a result of hostilities in the region or otherwise, and specifically following the Israel- Hamas war. In addition,
there have been increased efforts by activists to cause companies and consumers to boycott Israeli goods based on Israeli government
policies. Such actions, particularly if they become more widespread, may adversely impact our ability to sell our products.

There may be restrictions on transfers of our technology.

Yissum, received a total of 609,152 NIS in 2016
from the Israel Innovation Authority (IIA), which obligation has been assigned to LipoVation, our wholly-owned operating subsidiary.
We may in the future apply to receive additional grants from the IIA to support our research and development